HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text Full Text (PDF) Cardiosource Slide Set Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Saw, J. Search for Related Content PubMed Articles by Saw, J. Related Collections Related Article

Lack of Evidence of a Clopidogrel–Statin Interaction in the CHARISMA Trial

Jacqueline Saw, MD^_*, Danielle M. Brennan, MS, Steven R. Steinhubl, MD, Deepak L. Bhatt, MD, Koon-Hou Mak, MD, Keith Fox, MB, ChB^||, Eric J. Topol, MD^#,_* CHARISMA Investigators

^_* Division of Cardiology, Vancouver General Hospital, University of British Columbia, Vancouver, British Columbia, Canada
Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio
Department of Cardiovascular Medicine, University of Kentucky, Lexington, Kentucky
Gleneagles Medical Center, Singapore
^|| University and Royal Infirmary of Edinburgh, Edinburgh, Scotland, United Kingdom
^# Department of Cardiovascular Diseases, Scripps Clinic, La Jolla, California.

View larger version (28K): [in this window] [in a new window] [Download PPT slide]   Figure 1 CV Death, MI, and Stroke Primary end point of cardiovascular (CV) death, myocardial infarction (MI), or stroke at a median of 28 months among patients randomized to clopidogrel or placebo, according to statin administration. CYP3A4-MET = cytochrome P450 3A4-metabolized statin; HR = hazard ratio.